Moomoo AIのまとめ
Merck & Co., Inc., a leading pharmaceutical company, reported its first-quarter financial results for 2024 on April 25, 2024. The company announced a 9% increase in total worldwide sales to $15.8 billion compared to the first quarter of 2023, with a 12% growth excluding the impact of foreign exchange. Oncology and vaccines were significant contributors to the growth, with KEYTRUDA sales rising 20% to $6.9 billion and GARDASIL/GARDASIL 9 sales increasing 14% to $2.2 billion. The company's GAAP EPS was $1.87, while non-GAAP EPS was $2.07, both including a charge for the acquisition of Harpoon Therapeutics. Merck also received FDA approval for WINREVAIR, a treatment for adults with pulmonary arterial hypertension, and made progress in other therapeutic areas. The company raised its full-year 2024 financial outlook, expecting worldwide sales to be between $63.1 billion and $64.3 billion and non-GAAP EPS to be between $8.53 and $8.65. The report was signed by Corporate Secretary Kelly E. W. Grez.
Merck & Co., Inc., a leading pharmaceutical company, reported its first-quarter financial results for 2024 on April 25, 2024. The company announced a 9% increase in total worldwide sales to $15.8 billion compared to the first quarter of 2023, with a 12% growth excluding the impact of foreign exchange. Oncology and vaccines were significant contributors to the growth, with KEYTRUDA sales rising 20% to $6.9 billion and GARDASIL/GARDASIL 9 sales increasing 14% to $2.2 billion. The company's GAAP EPS was $1.87, while non-GAAP EPS was $2.07, both including a charge for the acquisition of Harpoon Therapeutics. Merck also received FDA approval for WINREVAIR, a treatment for adults with pulmonary arterial hypertension, and made progress in other therapeutic areas. The company raised its full-year 2024 financial outlook, expecting worldwide sales to be between $63.1 billion and $64.3 billion and non-GAAP EPS to be between $8.53 and $8.65. The report was signed by Corporate Secretary Kelly E. W. Grez.
2024年4月25日、主要な医薬品会社の一つであるMerck & Co., Inc.は、2024年第1四半期の財務結果を発表しました。同社は、2023年第1四半期に比べて、世界全体の売上高が9%増の158億ドル、外国為替の影響を除いた成長は12%増と発表しました。OncologyとVaccinesは成長に大きく貢献し、KEYTRUDAの売上高は20%増の69億ドル、GARDASIL/GARDASIL 9の売上高は14%増の22億ドルとなりました。同社のGAAP EPSは1.87ドル、非GAAP EPSは2.07ドルであり、どちらもHarpoon Therapeuticsの買収に関する費用が含ま...すべて展開
2024年4月25日、主要な医薬品会社の一つであるMerck & Co., Inc.は、2024年第1四半期の財務結果を発表しました。同社は、2023年第1四半期に比べて、世界全体の売上高が9%増の158億ドル、外国為替の影響を除いた成長は12%増と発表しました。OncologyとVaccinesは成長に大きく貢献し、KEYTRUDAの売上高は20%増の69億ドル、GARDASIL/GARDASIL 9の売上高は14%増の22億ドルとなりました。同社のGAAP EPSは1.87ドル、非GAAP EPSは2.07ドルであり、どちらもHarpoon Therapeuticsの買収に関する費用が含まれています。また、Merckは肺動脈性肺高血圧症の治療薬であるWINREVAIRのFDA承認を受け、他の治療領域でも進展を遂げています。同社は2024年の全世界の売上高が631億ドルから643億ドルの間に、非GAAP EPSが8.53ドルから8.65ドルの間になることを見込んで、2024年の業績予想を引き上げました。この報告書に署名したのは、コーポレート・セクレタリーのケリー・E・W・グレズでした。
役に立った
役に立たない